Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine

Human Gene Therapy

Volumn 16, Issue 11, 2005, Pages 1255-1266

  Kim, Jin H ^a   Majumder, Nilanjana ^a   Lin, Honghui ^a   Watkins, Simon ^a   Falo Jr , Louis D ^a,b   You, Zhaoyang ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; LENTIVIRUS VECTOR; NAKED DNA; TYROSINASE RELATED PROTEIN 2; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSDUCTION; GLIOBLASTOMA; HISTOPATHOLOGY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ANIMALS; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DNA PRIMERS; LENTIVIRUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VIRAL VACCINES;

ANIMALIA; LENTIVIRUS; MURINAE; MUS MUSCULUS;

EID: 27744484813     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1255     Document Type: Article

References (42)

1. AKBARI, O., DEKRUYFF, R., and UMETSU, D. (2001). Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2, 725-731.
2. BANCHEREAU, J., SCHULER-THURNER, B., PALUCKA, A.K., and SCHULER, G. (2001). Dendritic cells as vectors for therapy. Cell 106, 271-274.
3. BARGMANN, C., HUNG, M., and WEINBERG, R. (1986). The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230.
4. BELLONE, M., CANTARELLA, D., CASTIGLIONI, P., CROSTI, M.C., RONCHETTI, A., MORO, M., GARANCINI, M.P., CASORATI, G., and DELLABONA, P. (2000). Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165, 2651-2656.
5. BLOOM, M.B., PERRY-LALLEY, D., ROBBINS, P.F., LI, Y., ELGAMIL, M., ROSENBERG, S.A., and YANG, J.C. (1997). Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453-460.
6. BOON, T., and VAN DER BRUGGEN, P. (1996). Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
7. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4, 579-585.
8. BRECKPOT, K., DULLAERS, M., BONEHILL, A., VAN MEIRVENNE, S., HEIRMAN, C., DE GREEF, C., VAN DER BRUGGEN, P., and THIELEMANS, K. (2003). Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med. 5, 654-667.
9. CAPPELLO, P., TRIEBEL, F., IEZZI, M., CAORSI, C., QUAGLINO, E., LOLLINI, P.L., AMICI, A., DI CARLO, E., MUSIANI, P., GIOVARELLI, M., and FORNI, G. (2003). LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/new transgenic BALB/c mice. Cancer Res. 63, 2518-2525.
10. CHEN, C.H., WANG, T.L., HUNG, C.F., YANG, Y., YOUNG, R.A., PARDOLL, D.M., and WU, T.C. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042.
11. ESSLINGER, C., ROMERO, P., and MACDONALD, H. (2002). Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13, 1091-1100.
12. + T cell responses. J. Clin. Invest. 111, 1673-1681.
13. FIGDOR, C.G., DE VRIES, I.J., LESTERHUIS, W.J., and MELIEF, CJ. (2004). Dendritic cell immunotherapy: Mapping the way. Nat. Med. 10, 475-480.
14. FINN, O. (2003). Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3, 630-641.
15. FIRAT, H., ZENNOU, V., GARCIA-PONS, F., GINHOUX, F., COCHET, M., DANOS, O., LEMONNIER, F.A., LANGLADE-DEMOYEN, P., and CHARNEAU, P. (2002). Use of a lentiviral flap vector for induction of CTL immunity against melanoma: Perspectives for immunotherapy. J. Gene Med. 4, 38-45.
16. GURUNATHAN, S., KLINMAN, D., and SEDER, R. (2000). DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974.
17. HACEIN-BEY-ABINA, S., VON KALLE, C., SCHMIDT, M., LE DEIST, F., WULFFRAAT, N., McINTYRE, E., RADFORD, I., VILLEVAL, J.L., FRASER, C.C., CAVAZZANA-CALVO, M., and FISCHER, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256.
18. HAUSER, H., SHEN, L., GU, Q.L., KRUEGER, S., and CHEN, S.Y. (2004). Secretory heat-shock protein as a dendritic cell-targeting molecule: A new strategy to enhance the potency of genetic vaccines. Gene Ther. 11, 924-932.
19. HOUGHTON, A., GOLD, J., and BLACHERE, N. (2001). Immunity against cancer: Lessons learned from melanoma. Curr. Opin. Immunol. 13, 134-140.
20. HUNT, C., and MORIMOTO, R. (1985). Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotides sequence of human hsp70. Proc. Natl. Acad. Sci. U.S.A. 82, 6455-6459.
21. KIM, J.H., MAJUMDER, N., LIN, H., CHEN, J., FALO, L.D., Jr., and YOU, Z. (2005a). "Survival gene" Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther. (in press).
22. KIM, J.H., MAJUMDER, N., LIN, H., FALO, L.D., Jr., and YOU, Z. (2005b). Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol. Ther. 6, 941-949.
23. LOIS, C., HONG, E.J., PEASE, S., BROWN, E.J., and BALTIMORE, D. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872.
24. METHAROM, P., ELLEM, K.A., SCHMIDT, C., and WEI, M.Q. (2001). Lentiviral vector-mediated TRP2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 12, 2203-2213.
25. MILLAR, D.G., GARZA, K.M., ODERMATT, B., ELFORD, A.R., ONO, N., LI, Z., and OHASHI, P.S. (2003). Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med. 9, 1469-1476.
26. MILLER, M.J., HEJAZI, A.S., WEI, S.H., CAHALAN, M.D., and PARKER, I. (2004). T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc. Natl. Acad. Sci. U.S.A. 101, 998-1003.
27. MIYOSHI, H., BLOMER, U., TAKAHASHI, M., GAGE, F.H., and VERMA, I.M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157.
28. PALMOWSKI, M.J., LOPES, L., IKEDA, Y., SALIO, M., CERUNDOLO, V., and COLLINS, M.K. (2004). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 172, 1582-1587.
29. PARDOLL, D. (2002). Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2, 227-238.
30. PRINS, R., ODESA, S., and LIAU, L. (2003). Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63, 8487-8491.
31. ROSENBERG, S. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
32. STAVELEY-O'CARROLL, K., SOTOMAYOR, E., MONTGOMERY, I., BORRELLO, I., HWANG, L., FEIN, S., PARDOLL, D., and LEVITSKY, H. (1998). Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. U.S.A. 95, 1178-1183.
33. STEINMAN, R., and POPE, M. (2002). Exploiting dendritic cells to improve vaccine efficiency. J. Clin. Invest. 109, 1519-1526.
34. THEMIS, M., WADDINGTON, S.N., SCHMIDT, M., VON KALLE, C., WANG, Y., AL-ALLAF, F., GREGORY, L.G., NIVSARKAR, M., THEMIS, M., HOLDER, M.V., BUCKLEY, S.M., DIGHE, N., RUTHE, A.T., MISTRY, A., BIGGER, B., RAHIM, A., NGUYEN, T.H., TRONO, D., THRASHER, A.J., and COUTELLE, C. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12, 763-771.
35. TODRYK, S., GOUGH, M., and POCKLEY, G. (2003). Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 110, 1-9.
36. VANDENDRIESSCHE, T., THORREZ, L., NALDINI, L., FOLLENZI, A., MOONS, L., BERNEMAN, Z., COLLEN, D., and CHUAH, M.K. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100, 813-822.
37. VIGNA, E., and NALDINI, L. (2000). Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2, 308-316.
38. WAKKACH, A., FOURNIER, N., BRUN, V., BREITTMAYER, J.P., COTTREZ, F., and GROUX, H. (2003). Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617.
39. WANG, R.-F., and WANG, H.-Y. (2002). Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20, 149-154.
40. YOU, Z., HUANG, X., HESTER, J., TOH, H.C., and CHEN, S.Y. (2001). Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61, 3704-3711.
41. YU, Z., and RESTIFO, N.P. (2002). Cancer vaccines: Progress reveals new complexities. J. Clin. Invest. 110, 289-294.
42. ZUFFEREY, R., DULL, T., MANDEL, R.J., BUKOVSKY, A., QUIROZ, D., NALDINI, L., and TRONO, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880.